Acute myeloid leukemia trials in Denmark

In Denmark 20 Also abroad 761

20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Aarhus N, Copenhagen Oe, Odense C
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Copenhagen Oe, Odense C
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Aarhus N, Copenhagen Oe
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Aalborg, Copenhagen, Køge, Odense
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Copenhagen Oe
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C, Roskilde
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Aarhus N, Copenhagen Oe
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Aarhus N, Copenhagen Oe, Odense C
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
No phaseTaking people
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Where
Aalborg, Aarhus, Esbjerg, Herning, Odense, Roskilde, Vejle
Age
18 years and over
People
920
Run by
Christoffer Johansen
See details and how to joinNCT05444348
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Århus, Copenhagen Oe
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 2Taking people
VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study
Where
Aarhus N
Age
18 years and over
People
10
Run by
The University Of Birmingham
See details and how to join2024-516116-19-00 · EU 2024-516116-19-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Aalborg, Aarhus N, Copenhagen, Odense, Roskilde
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 2Taking people
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Where
Aarhus N, Copenhagen Oe
Age
1 month to 18 years
People
60 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01
Phase 3Taking people
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Where
Copenhagen
Age
Up to 18 years
People
170 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05477589
Phase 3Taking people
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Where
Aarhus N, Copenhagen Oe
Age
Up to 64 years
People
730 worldwide
Run by
Vaestra Goetalandsregionen
See details and how to joinNCT01828489 · EU 2024-518254-16-00
Phase 2Taking people
Combining Active and Passive DNA Hypomethylation
Where
Aalborg, Aarhus, Copenhagen, Odense, Roskilde
Age
18 years and over
People
196 worldwide
Run by
Kirsten Grønbæk
See details and how to joinNCT03999723
Phase 2Taking people
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Where
Aarhus N
Age
Up to 18 years
People
89 worldwide
Run by
Associazione Italiana Ematologia Oncologia Pediatrica
See details and how to joinNCT04793919 · EU 2024-518669-83-00
Phase 2Taking people
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
18 years and over
People
117 worldwide
Run by
Copenhagen University Hospital, Rigshospitalet
See details and how to joinNCT05431257 · EU 2023-510415-19-00